The dominant mechanism responsible for restenosis after angioplasty is believed to be the activation of medial smooth muscle cells (SMCs), leading to their proliferation, migration to the subintima, and further proliferation. To develop novel strategies that might inhibit or prevent restenosis, we previously used a chimeric toxin composed of transforming growth factor-at (which targets the epidermal growth factor receptor) and mutated Pseudomonas exotoxin to preferentially recognize and kill rapidly proliferating, versus quiescent, vascular SMCs. We have recently cloned and expressed a recombinant gene encoding Pseudomonas exotoxin with a mutated (nonfunctional) cell recognition domain fused with the ligand acidic fibroblast growth factor, termed aFGF-PE664GIUKDEL; thus, this recombinant toxin targets the fibroblast growth factor receptor. In the present study, we evaluated the relative effects of this chimeric toxin on quiescent versus rapidly proliferating vascular SMCs and also determined whether aFGF-PE664G!UKDEL exerted different effects on SMCs versus endothelial cells. Rapidly proliferating SMCs (grown in 10% fetal bovine serum) were very sensitive to the cytotoxic effects of aFGF-PE664GIuKDEL, whereas cytotoxicity was significantly less when the SMCs were in a quiescent state (grown in medium supplemented with 0.5% fetal bovine serum). The chimeric toxin was also significantly less cytotoxic against endothelial cells. Competition studies using excess acidic fibroblast growth factor indicated that the cytotoxic effects are specifically mediated by the fibroblast growth factor receptor. Thus, the present studies suggest a potentially expanded role of recombinant toxin therapy in restenosis: multiple receptors can be targeted, and cytotoxic effects, at least in vitro, can be preferentially directed to rapidly proliferating vascular SMCs, with relative sparing of vascular endothelial cells. It will next be necessary to test this strategy for inhibiting restenosis in an in vivo model of vascular injury and SMC proliferation.
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Chimeric Toxin
The plasmid encoding aFGF-PE664G`uKDEL ( Figure   1 ) was constructed as described. Figure 2 ; the toxin was markedly cytotoxic to rapidly proliferating SMCs and significantly less so against quiescent cells (at 10 ng/ml, p<0.05; at 100 ng/ml, p<0.001).
To determine whether protein synthesis inhibition reflected cell killing, we performed cell-staining and cell-counting assays. Cells were treated with aFGF-PE664GIUKDEL and counted or stained with methylene blue or with trypan blue as described in "Materials and Methods." Cell counting and cell staining with methylene blue demonstrated fewer SMCs when cells were exposed to aFGF-PE664G`uKDEL, an effect that was dose related (Figures 3 and 4 ). Since these results could be due to inhibition of proliferation rather than to cell killing, a cell-killing assay was performed using the trypan blue dye exclusion assay. Of the total cells counted per high-power field, 11% were dead at 24 hours, and 32% were dead at 48 hours. However, no dead cells were detected in the control groups.
Specificity of the Effects of aFGF Fusion Toxin on Protein Synthesis Inhibition
To determine whether the cytotoxic effects of aFGF-PE664GIUKDEL were due to the chimeric toxin itself and not to a bacterial contaminant derived during protein expression (such as E. coli endotoxin), dose-response curves using an inactive aFGF fusion toxin mutant were determined (aFGF-PE664Glu Asp553KDEL) No cytotoxic effect of this molecule on the SMCs was found at doses up to 1,000 ng/ml (Figures 3 and 5 ).
Receptor Mediation of Cytotoxic Effects of aFGF Fusion Toxin
To determine whether the cytotoxic effects of aFGF fusion toxin are specifically mediated by its binding to the FGF receptor, a competition assay using aFGF was performed on SMCs growing in 10% FBS. Excess aFGF added; column 2, 1 ng/ml; column 3, 10 ng!ml; column 4, 50 ng/ml; column 5, 250 ng!ml; column 6, 1,000 ng/ml.
(1,000-fold) blocked the inhibitory effects of aFGF-PE664GIUKDEL ( Figure 5 ).
Effects of aFGF-PE664G'uKDEL on Endothelial Cells Dose-response curves depicting the inhibitory effects on [3H]leucine incorporation of aFGF-PE664G`UKDEL against endothelial cells are shown in Figure 6 . The sensitivity of endothelial cells to the fusion toxin was significantly less (p<0.0025) than that of rapidly proliferating SMCs at 10 ng/ml and at 100 ng/ml ( Figure 6 ). Most interestingly, the concentration of toxin that exerted a nearly 50% inhibitory effect on rapidly proliferating SMCs (10 ng/ml) exerted no inhibitory effect on endothelial cells.
Discussion
We previously showed that rapidly proliferating SMCs overexpress the EGF receptor and that the chimeric toxin TGFa-PE40 (transforming growth fac- Additionally, aFGF-PE664Glu Asp553KDEL, a mutant of aFGF fusion toxin genetically engineered so that it is devoid of ADP-ribosylation activity but cloned, expressed, and purified in an identical manner to that used to produce the parent active molecule, had no cytotoxic effects on SMCs (Figures 3 and 5) .
Our finding that aFGF-PE664GIuKDEL was considerably more cytotoxic against rapidly proliferating SMCs than against quiescent SMCs may be of practical importance, because aFGF-PE664G'uKDEL would have little therapeutic potential if it killed all SMCs. The greater cytotoxic activity against rapidly proliferating cells raises the possibility that there may be a therapeutic window for the fusion toxin, in that it might be possible to target and selectively kill those SMCs that are activated and thence proliferate after angioplasty.
Although endothelial cells secrete substances that can either inhibit or stimulate SMC proliferation, they normally inhibit SMC proliferation.23,29-31 When angioplasty causes intimal denudation of endothelial cells, the regrowth of such cells (if they are functionally normal) would be expected to inhibit the subsequent development of excessive SMC proliferation and, thereby, the development of restenosis. Therefore, we determined whether the cytotoxic activity of the aFGF fusion toxin against SMCs is different from that against endothelial cells. We found that endothelial cells are significantly less sensitive to the cytotoxic effects of the fusion toxin than are SMCs ( Figure 6 ).
These in vitro studies provide further evidence suggesting a role for recombinant DNA-derived targeted therapy in restenosis. The main cause of restenosis after PTCA is injury-induced activation of SMCs, leading to their proliferation, migration to the subintima, and further proliferation.12-16Although the mechanisms responsible for these events are poorly understood,9-11,32-48 once SMCs are activated, they overexpress several cell surface receptors. 21 52 The present investigation demonstrates the in vitro effectiveness of targeting the FGF receptor with a fusion toxin, and our prior study demonstrated the effectiveness of targeting the EGF receptor. Moreover, preliminary results reported by Casscells et a152 indicate that the agent produced by the chemical conjugation of basic FGF to saporin (a potent plant toxin) also exerts cytotoxic effects on SMCs. Thus, multiple receptors can be targeted, and cytotoxic effects, at least in vitro, can be preferentially directed against rapidly proliferating SMCs, with relative sparing of quiescent SMCs and endothelial cells.
It must be emphasized, however, that the in vivo situation is considerably more complex. For example, the cytotoxic effects of the fusion toxins might cause dying SMCs to release FGF and other growth factors, which could stimulate contiguous SMCs to proliferate, and also saturate local FGF receptors and thereby inhibit the influence of the fusion toxin on other cells. Clearly, the next step in testing this strategy for inhibiting restenosis will be to determine whether the success achieved in vitro can also be achieved in vivo.
